Podcast: Play in new window | Download (Duration: 32:01 — 14.7MB)
Subscribe: RSS
Michael Fonstein of Cleveland Biolabs talked with Joyce in March 2010 about a new drug developed by his company that protects humans from the effects of radiation. The United States and other countries have been investing in this technology primarily for defense purposes, but medically it can also serve to assist in reducing the harmful effects of radiation from therapeutic radiation treatments for cancer, allowing the patient to continue treatment longer and reducing the side effects of the treatment.
In 2010 this treatment was just going into clinical trials. We are planning to interview a representative of Cleveland Biolabs in the coming weeks to get an update on the progress of this research. This program will serve to provide a base of understanding of the problem and the approach Cleveland Biolabs is pursuing.
Update: This drug is now called ENTOLIMOD (CBLB502) BIODEFENSE and is continuing through the validation process.
For more information, see http://www.cbiolabs.com
